GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies ...

The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the ...

Tens of thousands of Americans are in line to share $2.2bn (£1.7bn) after GSK agreed a settlement over claims its indigestion ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

Pharmaceutical giant GSK will pay up to £1.7billion to settle thousands of legal cases that claimed its heartburn drug Zantac ...

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...